Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations


10.74   -0.04 (-0.37%) 11-25 13:00
Open: 10.68 Pre. Close: 10.78
High: 10.7905 Low: 10.68
Volume: 24,431 Market Cap: 388(M)

Technical analysis

as of: 2022-11-25 1:56:35 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 12.63     One year: 14.76
Support: Support1: 9.24    Support2: 8.27
Resistance: Resistance1: 10.81    Resistance2: 12.63
Pivot: 10.28
Moving Average: MA(5): 10.5     MA(20): 10.14
MA(100): 8.27     MA(250): 7.38
MACD: MACD(12,26): 0.4     Signal(9): 0.4
Stochastic oscillator: %K(14,3): 94.9     %D(3): 89.8
RSI: RSI(14): 69.1
52-week: High: 10.81  Low: 5.13
Average Vol(K): 3-Month: 89 (K)  10-Days: 99 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ EDAP ] has closed below upper band by 5.0%. Bollinger Bands are 22.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.83 - 10.87 10.87 - 10.92
Low: 10.41 - 10.46 10.46 - 10.51
Close: 10.7 - 10.78 10.78 - 10.85

Company Description

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

Headline News

Wed, 23 Nov 2022
EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals - Simply Wall St

Tue, 22 Nov 2022 featured highlights include Immunocore Holdings, Old Second Bancorp, EDAP TMS, Barrett Business Services and MainStreet Bancshares - Yahoo Finance

Mon, 21 Nov 2022
EDAP to Present at the Piper Sandler 34th Annual Healthcare Conference - Ottumwacourier

Sun, 20 Nov 2022
EDAP Q3 Earnings: Building Momentum Around Focal One, Eying $15-$16.50 (NASDAQ:EDAP) - Seeking Alpha

Thu, 17 Nov 2022
EDAP TMS S.A. (EDAP) Q3 2022 Earnings Call Transcript - Seeking Alpha

Wed, 16 Nov 2022
EDAP TMS S.A. GAAP EPS of $0.00 beats by $0.05, revenue of $12.24M beats by $0.31M (NASDAQ:EDAP) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Devices
Shares Out. 36 (M)
Shares Float 29 (M)
% Held by Insiders 0 (%)
% Held by Institutions 37.2 (%)
Shares Short 43 (K)
Shares Short P.Month 69 (K)

Stock Financials

EPS 0.07
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.55
Profit Margin (%) 5
Operating Margin (%) -3.9
Return on Assets (ttm) -1.6
Return on Equity (ttm) 5
Qtrly Rev. Growth 36.7
Gross Profit (p.s.) 0.5
Sales Per Share 1.39
EBITDA (p.s.) -0.01
Qtrly Earnings Growth 0
Operating Cash Flow 5 (M)
Levered Free Cash Flow -2 (M)

Stock Valuations

PE Ratio 153.42
PEG Ratio 166.3
Price to Book value 6.88
Price to Sales 7.67
Price to Cash Flow 78.43

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.